Aurinia Pharmaceuticals Inc. — Form 8-K
Filed October 30, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
Aurinia reported Q3 2026 net product sales of $79.4M (+12% YoY) and nine-month sales of $232.4M (+18% YoY) for LUPKYNIS. Net income for nine months was $103.5M, up 35% from $76.4M in 2025. The company raised full-year 2026 total revenue guidance to $325–$330M (from $315–$325M) and narrowed net product sales guidance to $310–$315M (from $305–$315M). Cash position improved to $486.9M from $398.0M at year-end 2025. The company repurchased 5.0M shares for $74.9M and initiated PRESERVE, a Phase 4 combination study of LUPKYNIS with three biologic agents in ~150 lupus nephritis patients.
Why this rating
Double-digit revenue growth, 35% net income growth, and guidance raise are solid. Cash generation ($131.5M operating CF) and $88.9M net cash build support pipeline. ~$310–315M product sales ≈ 31–32% of $1B market cap—material but not transformational. Routine pharma execution.
See more from October 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.